58 results on '"Bauer, Douglas C"'
Search Results
2. Thyroid antibodies and levothyroxine effects in subclinical hypothyroidism: A pooled analysis of two randomized controlled trials
3. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project
4. Knowledge and Needs of Resident Physicians Regarding Osteoporosis: A Nationwide Survey of Residents
5. Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes
6. Osteoporosis Management in the Era of COVID‐19
7. Response to: Some Questions About the Article “The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report”
8. Commercial Laboratory Reproducibility of Serum CTX in Clinical Practice
9. Response Letter to the Editor—Diamond et al, JBMR
10. Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials
11. Biochemical Markers of Bone Turnover in Osteoporosis
12. Effect of Combination Folic Acid, Vitamin B6, and Vitamin B12 Supplementation on Fracture Risk in Women: A Randomized, Controlled Trial
13. Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting
14. Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
15. Goal‐Directed Treatment for Osteoporosis: A Progress Report From the ASBMR‐NOF Working Group on Goal‐Directed Treatment for Osteoporosis
16. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
17. Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data
18. Hyponatremia and Fractures: Findings From the MrOS Study
19. High hip fracture risk in men with severe aortic calcification: MrOS study
20. The Calcium Supplement Controversy: Now What?
21. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate
22. 25‐hydroxyvitamin D and adiposity in older black and white adults: the Health ABC study
23. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
24. Inflammatory markers and the risk of hip fracture: The women's health initiative
25. Height loss in older women: Risk of hip fracture and mortality independent of vertebral fractures
26. The potential value of monitoring bone turnover markers among women on alendronate
27. Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: The women's health initiative (WHI)
28. Effects of antiresorptive treatment on nonvertebral fracture outcomes
29. WHO absolute fracture risk models (FRAX): Do clinical risk factors improve fracture prediction in older women without osteoporosis?
30. Adipokines and the risk of fracture in older adults
31. The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial
32. Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?
33. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men
34. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelines
35. The value of routine BMD monitoring after starting bisphosphonate treatment
36. Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk
37. Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study
38. Effect of Adherence on Lifetime Fractures in Osteoporotic Women Treated With Daily and Weekly Bisphosphonates
39. Central nervous system medication use and incident mobility limitation in community elders: the health, aging, and body composition study
40. Self-Reported Sleep and Nap Habits and Risk of Mortality in a Large Cohort of Older Women
41. Cystatin‐C, Renal Function, and Incidence of Hip Fracture in Postmenopausal Women
42. Optimal Thresholds, Linear or Nonlinear Relationships of Fracture Risk Reduction With Therapy
43. Renal Function and Bisphosphonate Safety
44. Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial
45. Self-Reported Sleep and Nap Habits and Risk of Falls and Fractures in Older Women: The Study of Osteoporotic Fractures
46. Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial
47. Cortical PQCT Measures Are Associated With Fractures in Dialysis Patients
48. Prognostic Value of Usual Gait Speed in Well‐Functioning Older People—Results from the Health, Aging and Body Composition Study
49. Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women 65 Years of Age: The Study of Osteoporotic Fractures
50. Diabetes Is Associated Independently of Body Composition With BMD and Bone Volume in Older White and Black Men and Women: The Health, Aging, and Body Composition Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.